Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Bayer Schering Pharma AG
Woman and Man Max 99 years
Bayer Schering Pharma AG
Update Il y a 4 ans
Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC)
To investigate the efficacy of ZK 219477 in platinum-pretreated patients with NSCLC (proof of concept)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer Health Care AG (study performed by Bayer Schering Pharma AG)
Update Il y a 4 ans
An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1.0 molar (Gadovist®) in patients with newly diagnosed breast cancer referred for contrast-enhanced breast MRI
The primary objectives of this study are to demonstrate: 1. Superiority of combined unenhanced and gadobutrol-enhanced MRM versus unenhanced MRM 2. Superiority of combined unenhanced and gadobutrol-en...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Bayer HealthCare AG/Bayer Schering Pharma AG
Update Il y a 4 ans
Multicenter, open-label, randomized, uncontrolled study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestodene in healthy young female volunteers over a period of 3 treatment cycles
The primary objective of the study is to evaluate the inhibition of ovulation in treatment cycles 2 and 3 after administration of two different patches containing EE and GSD for 3 treatment cycles.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3